Pfizer's $10 Billion Bet on a Once-a-Month Weight Loss Shot

Mid-stage data from the VESPER-3 trial showed patients who switched from weekly to monthly dosing maintained about 12% weight loss at 28 weeks, with no plateau in sight. Only five patients dropped out due to side effects during the monthly phase. That's a clean tolerability profile by GLP-1 standards.

Wall Street's Verdict: Intrigued, Not Convinced

The reaction from analysts has been, to put it politely, a split decision.

Bulls point to the monthly dosing convenience and the fact that the weight-loss curve hasn't flattened yet. BMO and Scotiabank see the Metsera deal as giving Pfizer a platform, not just a single drug, with additional amylin and GIP receptor programs in the mix.

Bears, however, keep circling back to one number: 12% weight loss versus the over 20% that Lilly's Zepbound has shown in Phase 3 trials. Leerink Partners called the data "slightly inferior" to Zepbound when adjusted for placebo. Some investors openly question whether the $10 billion price tag for Metsera was justified by mid-stage results.

The stock has reflected that ambivalence. Shares dropped about 3% after one data release, then bounced 3 to 4% on a different day when the "monthly dosing works" headline led coverage. The market can't quite decide if Pfizer is a credible obesity contender or a late arrival overpaying for a ticket to a party that's already in full swing.

Why $17 Billion Is Breathing Down Pfizer's Neck

This obesity push isn't happening in a vacuum. It's happening because Pfizer is about to lose patent protection on some of its biggest earners.

Eliquis (blood thinner), Ibrance (breast cancer), Xtandi (prostate cancer), Prevnar 13 (vaccine), and Xeljanz (rheumatoid arthritis) all face U.S. patent expiries between 2026 and 2028. Together, they represent roughly $17 billion in annual revenue that's about to get hammered by generics.

That's the kind of revenue hole that makes CFOs lose sleep and CEOs make bold acquisitions. Pfizer has essentially told Wall Street: we know the cliff is coming, and obesity is how we climb back up.

CEO Albert Bourla has described obesity as a potential $150 billion global market by the early 2030s. He's framed 2024 through 2027 as an "investment and restructuring period," with the company targeting roughly $7.2 billion in cost savings by end of 2027, with the majority expected by end of 2026. About $500 million of those savings is being funneled directly back into R&D, with obesity and oncology as the primary beneficiaries.

The Crowded Track Pfizer Just Joined

Pfizer isn't just racing against Novo Nordisk and Eli Lilly anymore. The obesity field in 2026 looks like a packed starting line at the Boston Marathon.

Amgen has MariTide, its own once-monthly injectable with a different mechanism. Viking Therapeutics is pushing VK2735 in both oral and injectable forms. Roche (through its Carmot acquisition) is building an oral obesity pipeline. Even AstraZeneca and Boehringer Ingelheim are making moves.

The consensus among analysts is that the obesity market is big enough for multiple winners. But "multiple winners" doesn't mean "everyone wins." Pfizer needs its Phase 3 data to show weight loss creeping into the mid-teens percentage range, clean long-term safety, and manageable dropout rates. Anything less, and the company risks spending billions to become a second-tier player in a market where prescribers and payers already have proven options.

What Comes Next

Pfizer expects to start its 10 Phase 3 trials throughout 2026. The studies will test PF3944 across multiple patient populations: obese adults without diabetes (VESPER-4), obese adults with type 2 diabetes (VESPER-5), and several studies focused on obesity-related complications like cardiovascular disease.

If the data holds up, Pfizer is targeting a potential launch around 2028. That would be roughly three years behind Wegovy and Zepbound in the market; a lifetime in pharma, but not necessarily fatal if the monthly dosing story resonates with patients and payers.

The bottom line: Pfizer is making the single biggest corporate bet on obesity we've seen since Lilly and Novo built their empires. Ten billion dollars on an acquisition, 10 Phase 3 trials in a single year, and a patent cliff forcing the company to either innovate or shrink. The next 18 months will determine whether this was visionary capital allocation or the most expensive game of catch-up in biotech history.

Big Pharma Is Spending $300 Billion to Avoid a Single Tax

The Trump administration threatened 100% tariffs on imported branded drugs. Pharma's response? Over $300 billion in pledged U.S. manufacturing investments, a wave of direct-to-consumer sales channels, and the biggest reshoring scramble the industry has ever seen.